Thursday, September 17, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

Researchsemaglutidefinerenonesglt2diabetic kidney disease

Study compares semaglutide, finerenone and SGLT2 inhibitors in diabetic kidney disease

Diabetes, Obesity & Metabolism analysis weighs cardiorenal efficacy and safety of the agents alone and combined.

PR
By Priya Raman · Science Reporter
Sep 16 20:00 ETSource: Diabetes, obesity & metabolism

The wire

  1. 01Zhou and colleagues published a comparative analysis of finerenone, SGLT2 inhibitors, semaglutide and combinations in diabetic kidney disease.
  2. 02Clinicians face growing choices for cardiorenal protection in diabetes.
  3. 03Specific efficacy and safety results are not available from the citation alone.

From the source

Comparative Cardiorenal Efficacy and Safety of Finerenone, SGLT2 Inhibitors, Semaglutide and Their Combination in Diabetic Kidney Disease

Diabetes, obesity & metabolism · 2026 Sep 17 · Zhou Z, Fu L, Chen D et al.

Read at pubmed.ncbi.nlm.nih.gov
Source URL https://pubmed.ncbi.nlm.nih.gov/42750649/